Advancing the Care of Patients Living with EGPA Through Multidisciplinary, Patient-Focused Care
Released On
May 9, 2023
Expires On
May 9, 2024
Media Type
Internet
Completion Time
60 minutes
Specialty
Allergy & Immunology, Cardiology, Pulmonology, Rheumatology
Topic(s)
Eosinophilic granulomatosis with polyangiitis (EGPA)
This activity is jointly provided by Partners for Advancing Clinical Education and Iridium Continuing Education.
This activity is supported by an educational grant from GSK.
Credit Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This educational activity is intended for rheumatologists, allergists, immunologists, pulmonologists, and specialty advance practice clinicians who care for patients with EGPA.
Program Overview
The comprehensive program provides up-to-date information regarding EGPA—its recognition, diagnosis, and treatment—and incorporates the patient perspective to raise awareness of patients’ needs, heighten urgency, and, ultimately, educate on the disease. The program will explore new insights into the mechanisms of EGPA immunopathogenesis. Additionally, it will provide healthcare providers with an update on standard of care treatment options based for the different EGPA stages. A multidisciplinary approach to care is necessary to achieve optimal outcomes in EGPA. As such, this activity will provide clinicians with tools to better implement multidisciplinary, patient-centered approaches to care into their clinical practice.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Summarize the latest EGPA guidelines regarding early diagnosis and initiation of therapy considering the manifold possible presentations of EGPA
- List the signs and symptoms that may raise the index of suspicion for EGPA
- Select standard of care treatment and management options for different EGPA stages
- Explain patient-focused, multidisciplinary management tactics that can be implemented into clinical care to improve care for patients with EGPA
Faculty
Michael Wechsler, MD, MMSc (Chair)
Director, The Cohen Family Asthma Institute
Professor
Department of Medicine
Division of Pulmonary, Critical Care & Sleep Medicine
National Jewish Health
Denver, CO
Leonard Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Vice Chair, Department of Rheumatic and Immunologic Diseases
Director, Center for Vasculitis Care and Research
Director, Cleveland Clinic's RJ Fasenmyer Center for Clinical Immunology
Cleveland Clinic
Cleveland, OH
Anisha B. Dua, MD, MPH
Associate Professor
Fellowship Program Director
and Director of the Vasculitis Center
Division of Rheumatology
Northwestern University Feinberg School of Medicine,
Chicago, Il
Physician Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Iridium. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Credit Designation
PACE designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
PACE requires planners, faculty, and others who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies:
- Michael Wechsler, MD, MMSc
- Consultant, Advisor, or Speaker: Amgen, AstraZeneca, Avalo Therapeutics, Boehringer Ingelheim, Cereco, Cohero Health, Cytoreason, Eli Lilly, Equillium, GlaxoSmithKline, Incyte, Kinaset, Novartis, Om Pharma, Phylaxis, Pulmatrix, Rapt Therapeutics, Regeneron, Restorbio, Roche/Genentech, Sanofi/Genzyme, Sentien, Sound Biologics, Tetherex Pharmaceuticals, Teva, Upstream Bio
- Leonard Calabrese, DO
- Consultant, Advisor, or Speaker: AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Galvani, GlaxoSmithKline, Genentech, Janssen, Regeneron, Sanofi/Genzyme, UCB
- Anisha Dua, MD, MPH
- Consultant, Advisor, or Speaker: AbbVie, Chemocentryx, Novartis, Sanofi
The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The Iridium planners and others have no relevant financial relationship(s) to disclose with ineligible companies.
Instructions for Participation and Credit
In order to receive credit for this activity, the participant must:
- Read the learning objectives and faculty disclosures.
- Complete the pretest.
- View and participate in the activity.
- Complete the posttest with a score of 70% or higher
Fee Information and Refund/Cancellation Policy
There is no fee for this educational activity.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. PACE and Iridium do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information
For additional information about the accreditation of this activity, please visit https://partnersed.com